171 related articles for article (PubMed ID: 32704057)
21. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
Walts AE; Hiroshima K; Marchevsky AM
Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
[TBL] [Abstract][Full Text] [Related]
22. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.
Thomas de Montpréville V; Quilhot P; Chalabreysse L; De Muret A; Hofman V; Lantuéjoul S; Parrens M; Payan MJ; Rouquette I; Secq V; Girard N; Besse B; Marx A; Molina TJ
Pathol Res Pract; 2015 Dec; 211(12):996-1002. PubMed ID: 26534878
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Girard N; Shen R; Guo T; Zakowski MF; Heguy A; Riely GJ; Huang J; Lau C; Lash AE; Ladanyi M; Viale A; Antonescu CR; Travis WD; Rusch VW; Kris MG; Pao W
Clin Cancer Res; 2009 Nov; 15(22):6790-9. PubMed ID: 19861435
[TBL] [Abstract][Full Text] [Related]
24. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
25. Analysis of PRAME immunocytochemistry in 109 acral malignant melanoma in situ.
Miao QJ; Zang J; Shao XB; Sun JF; Chen YP; Chen H
J Clin Pathol; 2024 May; 77(6):417-420. PubMed ID: 36882315
[TBL] [Abstract][Full Text] [Related]
26. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
Alomari AK; Tharp AW; Umphress B; Kowal RP
J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
[TBL] [Abstract][Full Text] [Related]
27. Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma.
Tateyama H; Eimoto T; Tada T; Hattori H; Murase T; Takino H
Am J Clin Pathol; 1999 Feb; 111(2):235-40. PubMed ID: 9930146
[TBL] [Abstract][Full Text] [Related]
28. Immunohistological analysis of thymoma by molecules differentially expressed in the thymic cortex and medulla, and its application in the differential diagnosis of thymoma from esophageal and lung cancer.
Shiraishi J; Utsuyama M; Akashi T; Nemoto T; Ohashi K; Akamatsu H; Sunamori M; Kitagawa M; Hirokawa K
Pathol Res Pract; 2001; 197(9):611-9. PubMed ID: 11569925
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomas.
Roden AC; Yi ES; Jenkins SM; Donovan JL; Cassivi SD; Garces YI; Marks RS; Aubry MC
Hum Pathol; 2015 Jan; 46(1):17-25. PubMed ID: 25455993
[TBL] [Abstract][Full Text] [Related]
30. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
31. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
Chan JK; Tsang WY; Seneviratne S; Pau MY
Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
[TBL] [Abstract][Full Text] [Related]
32. Insulinoma-associated-1 (INSM1) expression in thymic squamous cell carcinoma.
Kashima J; Hashimoto T; Yoshida A; Goto Y; Ushiku T; Ohe Y; Watanabe SI; Yatabe Y
Virchows Arch; 2022 Dec; 481(6):893-901. PubMed ID: 36305944
[TBL] [Abstract][Full Text] [Related]
33. [Application of immunohistochemical staining of PRAME in differential diagnosis between melanoma and melanocytic nevus].
Du J; Yu WJ; Guo RP; Su J
Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):621-626. PubMed ID: 35785832
[No Abstract] [Full Text] [Related]
34. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets.
Enkner F; Pichlhöfer B; Zaharie AT; Krunic M; Holper TM; Janik S; Moser B; Schlangen K; Neudert B; Walter K; Migschitz B; Müllauer L
Pathol Oncol Res; 2017 Jul; 23(3):551-564. PubMed ID: 27844328
[TBL] [Abstract][Full Text] [Related]
35. Recurrent genetic aberrations in thymoma and thymic carcinoma.
Zettl A; Ströbel P; Wagner K; Katzenberger T; Ott G; Rosenwald A; Peters K; Krein A; Semik M; Müller-Hermelink HK; Marx A
Am J Pathol; 2000 Jul; 157(1):257-66. PubMed ID: 10880395
[TBL] [Abstract][Full Text] [Related]
36. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
37. Preferentially expressed antigen in melanoma expression in nonmelanoma skin cancers and melanocytes in surrounding skin.
Elsensohn A; Hanson J; Ferringer T
J Cutan Pathol; 2021 Sep; 48(9):1150-1155. PubMed ID: 33719089
[TBL] [Abstract][Full Text] [Related]
38. The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma.
Li H; Ren B; Yu S; Gao H; Sun PL
BMC Cancer; 2023 Feb; 23(1):161. PubMed ID: 36797681
[TBL] [Abstract][Full Text] [Related]
39. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
[TBL] [Abstract][Full Text] [Related]
40.
Baba H; Kanda M; Sawaki K; Shimizu D; Umeda S; Koike M; Kodera Y; Fujii T
Anticancer Res; 2019 Nov; 39(11):5943-5951. PubMed ID: 31704819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
